1: Aliment Pharmacol
Ther 1998 Jun;12(6):563-8
Treatment of Helicobacter pylori infection
in infants in rural Bangladesh with oral immunoglobulins from hyperimmune
bovine colostrum.
Casswall TH, Sarker SA, Albert MJ, Fuchs GJ, Bergstrom M, Bjorck L,
Hammarstrom L.
Department of Clinical Sciences, Huddinge Hospital, Karolinska Institute,
Sweden.
BACKGROUND: Antibodies from hyperimmune bovine colostrum have been
shown to be effective in treatment against a variety of microorganisms,
including Helicobacter pylori in adults. AIM: To test this form of
treatment in a small group of H. pylori infected children in a periurban
community in Bangladesh.
METHODS: Twenty-four infants, 4-29 months old (mean age 16.57.7 months)
and infected with H. pylori, were treated with purified immunoglobulins
from
hyperimmune bovine colostrum for 1 month, in a placebo-controlled,
double-blind pilot study. Diagnosis was established with 13C-urea
breath test (UBT) before and after the treatment period and at a 1-month
follow-up. RESULTS: None of the hyperimmune bovine colostrum-treated
children became UBT negative. Five children initially positive in
the UBT screening spontaneously became negative by the start of the
study with hyperimmune bovine colostrum/placebo. At the end of the
1-month study period, three had became positive again.
CONCLUSION: Hyperimmune bovine colostrum does not eradicate H. pylori
infection in infants. Transient H. pylori infection is common among
infants in high endemic areas, as is re-infection after clearance.
This presents obstacles to evaluation of therapeutic investigations
in young children in areas where H. pylori is prevalent.
Publication Types:
Clinical trial
Randomized controlled trial
PMID: 9678817 [PubMed - indexed for MEDLINE]
Articles
06
